Gene

TACSTD2

tumor associated calcium signal transducer 2

Curated evidence

Clinical evidence (2)

CIViC items involving this gene, grouped by molecular profile and therapy, with native levels and directions. 50 items per page.

civicCuratedShowing 1–2 of 2 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
TACSTD2 Overexpression1
(prognostic)	Malignant Prostate Neoplasm	Prognostic	B	Supports Poor Outcome	3	submitted	EID7837 Trop2 (TACSTD2) levels were evaluated from 234 patients who underwent radical prostatectomy. These levels were found to be significantly correlated with recurrence (P=0.01), with 58 patients displayin… (full text at CIViC) PMID 31932422 · Hsu et al., 2020 · Open in CIViC	civic
TACSTD2 T256R1
Sacituzumab Govitecan	Triple-Negative Breast CarcinomaALIAS	Predictive	B	Supports Resistance	3	submitted	EID12265 TROP2 T256R mutation alters the plasma membrane localization and cell-surface binding of hRS7, the humanized antibody incorporated into Sacituzumab Govitecan (SG). The TROP2 T256R encoded protein was …

Cohorts

Frequency = cases affected / cases profiled within one cohort. Cohorts are never pooled.

Data not yet available

No cohort frequency recorded for this gene.

Literature

Data not yet available

No publication linked to this gene yet.